TY - JOUR
T1 - Revisiting the issue of malignancy risk in systemic lupus erythematosus.
AU - Clarke, Ann E.
AU - Ramsey-Goldman, Rosalind
AU - Bernatsky, Sasha
N1 - Funding Information:
The authors would like to acknowledge the following grant support: S. Bernatsky—Canadian Institutes of Health Research [CIHR]/Lupus Canada Fellowship; CIHR Investi- gator Award; Canadian Arthritis Network Fellowship and Scholar Award; Lupus Manitoba Chapter Grant. R. Ramsey-Goldman—Arthritis Foundation, Clinical Science Grant, Arthritis Foundation Greater Chicago Chapter NIH # AR 02138, # AR 48098: Lupus Foundation of Illinois Chapter Grant A. Clarke—National Cancer Institute of Canada [NCIC] # 013135; The Arthritis Society # 99105; CIHR# 100005, 107012; Singer Family Fund for Lupus Research; CIHR Investigator Award.
PY - 2005/12
Y1 - 2005/12
N2 - Certain cancers occur more frequently in systemic lupus erythematosus (SLE) as compared with the general population, as recent data substantiates. The risk appears to be most heightened for lymphoma. Several pathogenic mechanisms may explain these observations, although little is definitively known. One particular concern relates to whether cancer risk in SLE is increased by medication exposures. Cooperative efforts to evaluate this have been undertaken by the Systemic Lupus International Collaborating Clinics and the Canadian Network for Improved Outcomes in Systemic Lupus research groups. This and other works in progress will, it is hoped, considerably advance the knowledge regarding the association between autoimmune diseases and malignancy.
AB - Certain cancers occur more frequently in systemic lupus erythematosus (SLE) as compared with the general population, as recent data substantiates. The risk appears to be most heightened for lymphoma. Several pathogenic mechanisms may explain these observations, although little is definitively known. One particular concern relates to whether cancer risk in SLE is increased by medication exposures. Cooperative efforts to evaluate this have been undertaken by the Systemic Lupus International Collaborating Clinics and the Canadian Network for Improved Outcomes in Systemic Lupus research groups. This and other works in progress will, it is hoped, considerably advance the knowledge regarding the association between autoimmune diseases and malignancy.
UR - http://www.scopus.com/inward/record.url?scp=33645867697&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33645867697&partnerID=8YFLogxK
U2 - 10.1007/s11926-005-0055-2
DO - 10.1007/s11926-005-0055-2
M3 - Review article
C2 - 16303109
AN - SCOPUS:33645867697
VL - 7
SP - 476
EP - 481
JO - Current Rheumatology Reports
JF - Current Rheumatology Reports
SN - 1523-3774
IS - 6
ER -
